Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025

This “Axial spondyloarthritis (axSpA) - Pipeline Insight, 2025” report provides comprehensive insights about 15+companies and 15+pipeline drugs in Axial spondyloarthritis (axSpA) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Axial spondyloarthritis (axSpA): Understanding

Axial spondyloarthritis (axSpA): Overview

Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, which connect the lower spine to the pelvis. It falls under the broader category of spondyloarthritis, which includes various inflammatory conditions affecting the joints and sometimes other tissues in the body.

Axial spondyloarthritis typically manifests as chronic back pain and stiffness, which often worsens with rest and improves with physical activity. The hallmark feature of axSpA is inflammation of the sacroiliac joints, leading to pain and stiffness in the lower back and buttocks. Over time, if left untreated, axSpA can cause structural damage to the spine, resulting in fusion of the vertebrae (ankylosis) and reduced mobility.

The exact cause of axSpA is not fully understood, but it is believed to involve a combination of genetic predisposition and environmental factors. The condition tends to affect young adults, with symptoms often starting in late adolescence or early adulthood. Men are more commonly affected than women.

Diagnosis of axSpA typically involves a combination of clinical evaluation, imaging studies such as X-rays and MRI scans, and blood tests to assess for markers of inflammation. Treatment aims to reduce pain and inflammation, improve mobility, and prevent long-term joint damage. This may include medications such as nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), biologic therapies, and physical therapy.

Early diagnosis and intervention are crucial in managing axSpA and preventing complications. With appropriate treatment and lifestyle modifications, many individuals with axSpA are able to manage their symptoms and maintain a good quality of life. However, the course of the disease can vary widely among individuals, and ongoing monitoring and adjustments to treatment may be necessary to effectively manage symptoms and prevent progression.

'Axial spondyloarthritis (axSpA)- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axial spondyloarthritis (axSpA) pipeline landscape is provided which includes the disease overview and Axial spondyloarthritis (axSpA) treatment guidelines. The assessment part of the report embraces, in depth Axial spondyloarthritis (axSpA) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axial spondyloarthritis (axSpA) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Axial spondyloarthritis (axSpA) R&D. The therapies under development are focused on novel approaches to treat/improve Axial spondyloarthritis (axSpA).

Axial spondyloarthritis (axSpA) Emerging Drugs Chapters

This segment of the Axial spondyloarthritis (axSpA) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axial spondyloarthritis (axSpA) Emerging Drugs

Filgotinib: Galapagos NV

Filgotinib is marketed as Jyseleca in Europe and Japan for the treatment of adults with moderate to severe active rheumatoid arthritis (RA) who have responded inadequately or are intolerant to one or more disease modifying anti-rheumatic drugs (DMARDs). Filgotinib is also marketed as Jyseleca in Europe and Japan for the treatment of adult patients with moderate to severe active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Filgotinib is a JAK1 preferential inhibitor orally administered once daily, and is currently in Phase III trial in axial spondyloarthritis (AxSpA).

SHR0302: Jiangsu Hengrui Pharmaceutical Co., Ltd.

SHR0302 is a highly selective JAK1 inhibitor, which can exert anti-inflammatory and immune-suppressing biological effects by inhibiting JAK1 signal transduction, and is clinically planned for the treatment of active radiologically negative axial spondyloarthritis. SHR0302 tablets are expected to become a new treatment option for active nr-axSpA, benefiting the majority of nr-axSpA patients. SHR0302 is in the Phase III stage of its development for the treatment of ankylosing spondylitis.

SCT650C: Sinocelltech

SCT650C is a novel humanized monoclonal antibody against human IL-17A developed by Sinocelltech. Interleukin-17A (IL-17A) is a new potential therapeutic target which plays important role in pathogenesis of several autoimmune disorders. Currently, the drug is being evaluated in the Phase II stage of its develoment for treatment of ankylosing spondylitis.

Axial spondyloarthritis (axSpA): Therapeutic Assessment

This segment of the report provides insights about the different Axial spondyloarthritis (axSpA) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Axial spondyloarthritis (axSpA)

There are approx. 15+key companies which are developing the therapies for Axial spondyloarthritis (axSpA). The companies which have their Axial spondyloarthritis (axSpA) drug candidates in the most advanced stage, i.e. phase III include, Galapagos NV.

Phases

The report covers around 15+products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Axial spondyloarthritis (axSpA) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axial spondyloarthritis (axSpA): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axial spondyloarthritis (axSpA) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axial spondyloarthritis (axSpA) drugs.

Axial spondyloarthritis (axSpA) Report Insights

• Axial spondyloarthritis (axSpA) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Axial spondyloarthritis (axSpA) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Axial spondyloarthritis (axSpA) drugs?
• How many Axial spondyloarthritis (axSpA) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Axial spondyloarthritis (axSpA)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Axial spondyloarthritis (axSpA) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Axial spondyloarthritis (axSpA) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Galapagos NV
• Jiangsu Hengrui Pharmaceutical Co., Ltd.

Akeso, Inc.

Izana Bioscience Ltd.

Biocad

• Mabpharm Limitied
• Shilpa Biologicals

Key Products

• Filgotinib
• SHR0302
• AK111
• Namilumab
• BCD-180
• CMAB015
• SBDM-002

This product will be delivered within 2 business days.